Distinguished in Angiosarcoma

Dr. Mahsa M. Mohebtash

Hematology Oncology | Hematology | Oncology
Medstar Medical Group Ii LLC
9000 Franklin Square Dr, 
Baltimore, MD 
Accepting New Patients
Offers Telehealth
Distinguished in Angiosarcoma
Medstar Medical Group Ii LLC
9000 Franklin Square Dr, 
Baltimore, MD 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Mahsa Mohebtash is a Hematologist Oncology specialist and a Hematologist in Baltimore, Maryland. Dr. Mohebtash is rated as a Distinguished provider by MediFind in the treatment of Angiosarcoma. Her top areas of expertise are Breast Cancer, Inflammatory Breast Cancer, Angiosarcoma, and Paget Disease of the Breast. Dr. Mohebtash is currently accepting new patients.

Her clinical research consists of co-authoring 17 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in MD
Hospital Affiliations
Medstar Franklin Square Medical Center
Medstar Union Memorial Hospital
Medstar Good Samaritan Hospital
Languages Spoken
English
Farsi
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Johns Hopkins Healthcare
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE-MEDICAID PLAN
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 7 Less Insurance Carriers -

Locations

MEDSTAR MEDICAL GROUP II LLC
9000 Franklin Square Dr, Baltimore, MD 21237

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer With Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer
A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer With Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Drug, Other
Study Drugs: Anastrozole, Exemestane, Letrozole, Systemic Chemotherapy
Study Phase: Phase 3
Alternate Approaches for Clinical Stage II or III Estrogen Receptor Positive Breast Cancer Neoadjuvant Treatment (ALTERNATE) in Postmenopausal Women: a Phase III Study
Alternate Approaches for Clinical Stage II or III Estrogen Receptor Positive Breast Cancer Neoadjuvant Treatment (ALTERNATE) in Postmenopausal Women: a Phase III Study
Enrollment Status: Active_not_recruiting
Publish Date: January 10, 2025
Intervention Type: Drug
Study Drugs: Fulvestrant, Anastrozole
Study Phase: Phase 3
Phase II Trial of Combination Immunotherapy With Nelipepimut-S + GM-CSF (NeuVax™) and Trastuzumab in High-risk HER2+ Breast Cancer Patients
Phase II Trial of Combination Immunotherapy With Nelipepimut-S + GM-CSF (NeuVax™) and Trastuzumab in High-risk HER2+ Breast Cancer Patients
Enrollment Status: Completed
Publish Date: December 12, 2023
Intervention Type: Biological, Drug
Study Drugs: NeuVax vaccine, Trastuzumab, GM-CSF
Study Phase: Phase 2
OASIS: Phase II Trial of OrAl SM-88 in Patients With Metastatic Hormone Receptor-posItive HER2-negative (HR+/HER2-) breaSt Cancer
OASIS: Phase II Trial of OrAl SM-88 in Patients With Metastatic Hormone Receptor-posItive HER2-negative (HR+/HER2-) breaSt Cancer
Enrollment Status: Terminated
Publish Date: August 28, 2023
Intervention Type: Drug
Study Drug: SM-88
Study Phase: Phase 2
Diarrhea Prevention and Prophylaxis With Crofelemer in HER2 Positive Breast Cancer Patients Receiving Trastuzumab, Pertuzumab, and Docetaxel or Paclitaxel With or Without Carboplatin: HALT-D
Diarrhea Prevention and Prophylaxis With Crofelemer in HER2 Positive Breast Cancer Patients Receiving Trastuzumab, Pertuzumab, and Docetaxel or Paclitaxel With or Without Carboplatin: HALT-D
Enrollment Status: Completed
Publish Date: October 24, 2022
Intervention Type: Drug
Study Drug: Crofelemer
Study Phase: Phase 2
Phase II Safety Study of Palbociclib in Combination With Letrozole or Fulvestrant in African American Women With Hormone Receptor Positive HER2 Negative Advanced Breast Cancer
Phase II Safety Study of Palbociclib in Combination With Letrozole or Fulvestrant in African American Women With Hormone Receptor Positive HER2 Negative Advanced Breast Cancer
Enrollment Status: Completed
Publish Date: September 28, 2021
Intervention Type: Drug
Study Drug: Palbociclib + Letrozole or Fulvestrant
Study Phase: Phase 2/Phase 3
Combination Immunotherapy With Herceptin and the HER2 Vaccine E75 in Low and Intermediate HER2-expressing Breast Cancer Patients to Prevent Recurrence
Combination Immunotherapy With Herceptin and the HER2 Vaccine E75 in Low and Intermediate HER2-expressing Breast Cancer Patients to Prevent Recurrence
Enrollment Status: Completed
Publish Date: December 02, 2020
Intervention Type: Drug
Study Phase: Phase 2
View 6 Less Clinical Trials

17 Total Publications

A Rare Discovery of Neuroendocrine Tumor: Cardiac Mass.
A Rare Discovery of Neuroendocrine Tumor: Cardiac Mass.
Journal: Journal of community hospital internal medicine perspectives
Published: December 16, 2024
Similar Doctors
Distinguished in Angiosarcoma
Dr. Mary J. Wilkinson
Oncology | Hematology | Hematology Oncology
Distinguished in Angiosarcoma
Dr. Mary J. Wilkinson
Oncology | Hematology | Hematology Oncology

Johns Hopkins University

5255 Loughboro Rd Nw, 
Washington, DC 
 (44.3 miles away)
202-537-4000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Mary Wilkinson is an Oncologist and a Hematologist in Washington, Washington, D.c.. Dr. Wilkinson is rated as a Distinguished provider by MediFind in the treatment of Angiosarcoma. Her top areas of expertise are Angiosarcoma, Paget Disease of the Breast, Breast Cancer, and Inflammatory Breast Cancer.

Distinguished in Angiosarcoma
Dr. David A. Riseberg
Oncology | Hematology
Distinguished in Angiosarcoma
Dr. David A. Riseberg
Oncology | Hematology

St Paul Place Specialists Inc

301 Saint Paul St, 
Baltimore, MD 
 (8.2 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients

David Riseberg is an Oncologist and a Hematologist in Baltimore, Maryland. Dr. Riseberg is rated as a Distinguished provider by MediFind in the treatment of Angiosarcoma. His top areas of expertise are Breast Cancer, Angiosarcoma, Paget Disease of the Breast, and Inflammatory Breast Cancer. Dr. Riseberg is currently accepting new patients.

Distinguished in Angiosarcoma
Dr. Pavani Chalasani
Hematology Oncology | Hematology | Oncology
Distinguished in Angiosarcoma
Dr. Pavani Chalasani
Hematology Oncology | Hematology | Oncology

Medical Faculty Associates, Inc

2150 Pennsylvania Ave Nw, 
Washington, DC 
 (43.5 miles away)
202-741-2600
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Pavani Chalasani is a Hematologist Oncology specialist and a Hematologist in Washington, Washington, D.c.. Dr. Chalasani is rated as a Distinguished provider by MediFind in the treatment of Angiosarcoma. Her top areas of expertise are Breast Cancer, Inflammatory Breast Cancer, Angiosarcoma, and Paget Disease of the Breast. Dr. Chalasani is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Mohebtash's expertise for a condition
ConditionClose
    View All 37 Advanced Conditions
    View All 150 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile